Abstract 1514P
Background
At interim analysis (IA) of RATIONALE-306 (NCT03783442), 1L TIS + chemo demonstrated a statistically significant, clinically meaningful improvement in overall survival (OS) vs PBO + chemo, with a manageable safety profile, in patients (pts) with advanced/metastatic ESCC. Here, we report updated efficacy and safety data with minimum (min) 2 years’ follow-up.
Methods
Adults with unresectable locally advanced recurrent/metastatic ESCC and no prior systemic treatment for advanced disease were enrolled and randomized (1:1; stratified by region, prior definitive therapy, and investigator [INV]-chosen chemo) to receive TIS 200 mg (Arm A) or PBO (Arm B) IV Q3W + chemo (platinum + fluoropyrimidine or platinum + paclitaxel), until disease progression, intolerable toxicity, or withdrawal. The primary endpoint was OS in the intent-to-treat population. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) per INV, and safety.
Results
649 pts were randomized (Arm A n=326, Arm B n=323). At data cutoff (Dec 31, 2022), min study follow-up was 25.2 months; improvements in OS, PFS, ORR, and DoR in Arm A vs B (Table) were maintained relative to the IA. Similar to the IA, incidences of any-grade (96.6% vs 96.3%) or ≥grade 3 (66.7% vs 64.5%) treatment-related adverse events (TRAEs) were comparable between Arms A and B, respectively; treatment-emergent adverse events leading to treatment discontinuation were higher in Arm A (31.8%) vs B (22.1%). In Arm A vs B, respectively, serious TRAEs occurred in 29.3% vs 19.6% of pts; TRAEs leading to death occurred in 1.9% and 1.2%.
Table: 1514P
Arm A: TIS + chemo (n=326) | Arm B: PBO + chemo (n=323) | |
mOS, mo (95% CI) HR (95% CI) | 17.2 (15.8, 20.1) | 10.6 (9.3, 12.1) |
0.67 (0.56, 0.80) | ||
24-mo OS, % (95% CI) | 37.9 (32.5, 43.2) | 25.0 (20.2, 30.0) |
mPFS, mo (95% CI) a HR (95% CI) | 7.3 (6.9, 8.3) | 5.6 (4.9, 6.0) |
0.61 (0.51, 0.73) | ||
24-mo PFS, % (95% CI) | 18.1 (13.6, 23.1) | 7.2 (4.4, 11.0) |
ORR, % (95% CI) a | 63.5 (58.0, 68.7) | 42.4 (37.0, 48.0) |
mDoR, mo (95% CI) a | 7.1 (6.1, 8.1) | 5.7 (4.4, 7.1) |
24-mo DoR, % (95% CI) | 19.6 (13.9, 25.9) | 10.1 (5.0, 17.1) |
aPer INV. CI, confidence interval; HR, hazard ratio; m, median; mo, months. |
Conclusions
After min 2 years’ follow-up, 1L TIS + chemo continued to demonstrate clinically meaningful improvements in OS and PFS and durable tumour response benefit vs PBO + chemo in pts with advanced/metastatic ESCC, with no new safety signals.
Clinical trial identification
NCT03783442.
Editorial acknowledgement
Medical writing support, under the direction of the authors, was provided by Adeline Lum Nde, PhD, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
R. Hubner: Financial Interests, Invited Speaker: Eisai; Financial Interests, Advisory Board: BeiGene; Financial Interests, Advisory Role: Novartis, Ipsen. K. Kato: Financial Interests, Speaker’s Bureau: Ono, BMS, MSD; Financial Interests, Research Grant: ONO; Financial Interests, Principal Investigator: BMS, Ono, MSD, Bayer, BeiGene, AstraZeneca; Financial Interests, Advisory Role: BMS, Ono, MSD, Bayer, BeiGene, AstraZeneca, Seagen, Servier. T. Kojima: Financial Interests, Invited Speaker: MSD, Bristol Myers Squibb, Ono Pharmaceutical; Financial Interests, Advisory Board: Boehringer Ingelheim, Kyowa Kirin, Taiho Pharmaceutical; Financial Interests, Research Grant: AstraZeneca, BeiGene, MSD, Amgen, Chugai Pharmaceutical, Taiho Pharmaceutical, Shionogi Pharma, Amgen Astellas BioPharma. L.S. Wyrwicz: Financial Interests, Personal, Advisory Board: BMS, Servier; Financial Interests, Personal and Institutional, Invited Speaker: BMS, MSD, Servier, BeiGene, Roche, AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca. H. Wu: Financial Interests, Full or part-time Employment: BeiGene; Financial Interests, Stocks/Shares: BeiGene. Y. Peng: Financial Interests, Full or part-time Employment: BeiGene. L. Wang: Other, Full or part-time Employment, Full time employment: BeiGene. L. Li: Financial Interests, Full or part-time Employment: BeiGene; Financial Interests, Stocks/Shares: BeiGene; Financial Interests, Training: BeiGene. H.H. Yoon: Financial Interests, Institutional, Invited Speaker: BeiGene; Non-Financial Interests, Writing Engagement: BeiGene; Financial Interests, Personal, Expert Testimony: MJH Life Sciences; Financial Interests, Institutional, Advisory Board: ALX Oncology, AstraZeneca, BeiGene, Bristol Myers Squibb, Macrogenics, Merck, OncXerna, Zymeworks, Novartis, Astellas, Amgen, Elevation Oncology; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, CARsgen Therapeutics, Merck, BeiGene; Financial Interests, Institutional, Other, Support for travel: BeiGene. All other authors have declared no conflicts of interest.
Resources from the same session
1554P - Clinical Impact of ERBB2 copy number and tumor mutation burden (TMB) in patients with HER2- positive advanced gastric cancer treated by nivolumab (N-mab) plus trastuzumab (T-mab) and standard chemotherapy
Presenter: Hirokazu Shoji
Session: Poster session 21
1555P - Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study
Presenter: Alexandre Harlé
Session: Poster session 21
1556P - Pharmacokinetics, pharmacodynamics and exposure response analyses of osemitamab in patients with locally advanced or metastatic solid tumors
Presenter: Lin Shen
Session: Poster session 21
1557P - Single-cell RNA-seq dissecting the initiating liver metastasis cells and liver metastatic microenvironment in gastric cancer
Presenter: Shu-yue Zheng
Session: Poster session 21
1558P - Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial
Presenter: hongjing jiang
Session: Poster session 21
1559P - PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis
Presenter: Manavi Sachdeva
Session: Poster session 21
1560P - Osemitamab (TST001): An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1/PD-1 mab and oxaliplatin/5-FU in preclinical tumor models
Presenter: Xueming Qian
Session: Poster session 21
1561P - APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)
Presenter: Takeru Wakatsuki
Session: Poster session 21
1562P - Claudin 18.2 expression in resected gastric cancer
Presenter: Mitsuhiro Furuta
Session: Poster session 21
1563P - Tumor-intrinsic subtypes of esophageal adenocarcinoma associate cellular phenotypes with responses to therapy
Presenter: Dionne Blangé
Session: Poster session 21